CTNNB1 and neoplasm: TTK inhibitors exhibit heightened sensitivity toward tumor cells harboring CTNNB1 mutations, implicating CTNNB1 mutations as predictive genetic markers for patient response to TTK inhibitor therapy (Zaman et al., 2017).